ABIONYX Pharma SA (CEREN):企業の財務・戦略的SWOT分析

◆英語タイトル:ABIONYX Pharma SA (CEREN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140130FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ABIONYX Pharma SA (ABIONYX) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. Its therapies include CER-001 a negatively-charged lipoprotein particle that find application in atheosclerotic plaque regression; and CER-209 is a simulator of HDL receptors. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. ABIONYX works in partnership with other research and biotechnology companies for the development of HDL drug delivery products and technologies. The company has presence in France and the US. Cerenis is headquartered in France.

ABIONYX Pharma SA Key Recent Developments

Feb 25,2021: ABIONYX Pharma: annual results 2020
Feb 04,2021: ABIONYX Pharma provides an update on its cash position and the start of its clinical activities in Q4 2020
Oct 22,2020: ABIONYX announces its cash position and provides an activity update for the 3rd quarter 2020
Sep 10,2020: ABIONYX Pharma: 2020 Half-year results
Apr 23,2020: Gross cash position and business review for the first quarter of 2020

This comprehensive SWOT profile of ABIONYX Pharma SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ABIONYX Pharma SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ABIONYX Pharma SA – Key Information
ABIONYX Pharma SA – Overview
ABIONYX Pharma SA – Key Employees
ABIONYX Pharma SA – Key Employee Biographies
ABIONYX Pharma SA – Key Operational Heads
ABIONYX Pharma SA – Major Products and Services
ABIONYX Pharma SA – History
ABIONYX Pharma SA – Company Statement
ABIONYX Pharma SA – Locations And Subsidiaries
ABIONYX Pharma SA
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ABIONYX Pharma SA – Business Description
ABIONYX Pharma SA – Corporate Strategy
ABIONYX Pharma SA – SWOT Analysis
SWOT Analysis – Overview
ABIONYX Pharma SA – Strengths
ABIONYX Pharma SA – Weaknesses
ABIONYX Pharma SA – Opportunities
ABIONYX Pharma SA – Threats
ABIONYX Pharma SA – Key Competitors

Section 3 – Company Financial Performance Charts

ABIONYX Pharma SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ABIONYX Pharma SA, Key Information
ABIONYX Pharma SA, Key Ratios
ABIONYX Pharma SA, Share Data
ABIONYX Pharma SA, Major Products and Services
ABIONYX Pharma SA, History
ABIONYX Pharma SA, Key Employees
ABIONYX Pharma SA, Key Employee Biographies
ABIONYX Pharma SA, Key Operational Heads
ABIONYX Pharma SA, Other Locations
ABIONYX Pharma SA, Subsidiaries
ABIONYX Pharma SA, Key Competitors
ABIONYX Pharma SA, SWOT Analysis
ABIONYX Pharma SA, Ratios based on current share price
ABIONYX Pharma SA, Annual Ratios
ABIONYX Pharma SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ABIONYX Pharma SA (CEREN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lenenergo (LSNG):企業の財務・戦略的SWOT分析
    Lenenergo (LSNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • iBio Inc (IBIO):医療機器:M&Aディール及び事業提携情報
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • Emergent BioSolutions Inc (EBS):医療機器:M&Aディール及び事業提携情報
    Summary Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It …
  • BELLUS Health Inc (BLU):製薬・医療:M&Aディール及び事業提携情報
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …
  • Collins Foods Ltd (CKF):企業の財務・戦略的SWOT分析
    Collins Foods Ltd (CKF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hitachi Construction Machinery Co., Ltd. (6305):企業の財務・戦略的SWOT分析
    Hitachi Construction Machinery Co., Ltd. (6305) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Cajun Industries, LLC:企業の戦略的SWOT分析
    Cajun Industries, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • VINCI Energies:電力:M&Aディール及び事業提携情報
    Summary VINCI Energies S.A. (Vinci), a subsidiary of Vinci SA, is a provider of energy efficiency and renewable energy solutions. The company offers heating, ventilation and air conditioning, electric power, mechanical engineering and information and communications technologies. Vinci operates in mu …
  • Cell Signaling Technology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cell Signaling Technology Inc (CST) is a biological research and diagnostic products provider. The company offers primary antibodies, antibody samplers, secondary antibodies, antibody conjugates, elisa kits, chip kits and reagents proteomic analysis products, cellular assay kits, WB and IP r …
  • Sandoz Inc:企業の戦略的SWOT分析
    Sandoz Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Energy Metals Ltd (EME):企業の財務・戦略的SWOT分析
    Summary Energy Metals Ltd (Energy Metals) is a mining and mineral exploration company that focuses on the development of mineral resources in Australia. It acquires, explores, operates, manages, produces, and develops uranium, vanadium, and mineral resource deposit properties. Energy Metals' project …
  • Green Plains Inc.:企業のM&A・事業提携・投資動向
    Green Plains Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Green Plains Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • At Home Group Inc. (HOME):企業の財務・戦略的SWOT分析
    At Home Group Inc. (HOME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Greentech Energy Systems AS (GES)-エネルギー分野:企業M&A・提携分析
    Summary Greentech Energy Systems AS (Greentech) is an energy company which operates renewable energy plants. It generates electricity from wind and solar sources. Through long-term power purchase agreements, the company sells electricity. Greentech expands its asset portfolio through inorganic growt …
  • Damco International B.V.:企業の戦略・SWOT・財務分析
    Damco International B.V. - Strategy, SWOT and Corporate Finance Report Summary Damco International B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • VistaGen Therapeutics Inc (VTGN):製薬・医療:M&Aディール及び事業提携情報
    Summary VistaGen Therapeutics Inc (VistaGen) is a biopharmaceutical company that develops new generation medicines for neuropsychiatric disorders. The company’s product includes AV-101, which is a oral antidepressant which is currently under clinical study in National Institute of Mental Health (NIM …
  • Mycenax Biotech Inc (4726):企業の財務・戦略的SWOT分析
    Summary Mycenax Biotech Inc (Mycenax) is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company provides pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, …
  • Fauji Fertilizer Co Ltd (FFC):企業の財務・戦略的SWOT分析
    Fauji Fertilizer Co Ltd (FFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • RSA Insurance Group plc:企業の戦略・SWOT・財務情報
    RSA Insurance Group plc - Strategy, SWOT and Corporate Finance Report Summary RSA Insurance Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Indivumed GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Indivumed GmbH (Indivumed) is an oncology company that provides solutions for diagnosis and treatment of cancer. The company is involved in the generation, characterization, and analysis of biologic samples from human cancer patients. It offers biospecimen products and clinical data sets; an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆